General
Preferred name
TELAPREVIR
Synonyms
VX-950 ()
LY-570310 ()
Incivek ()
MP-424 ()
Telaprevir (VX-950) ()
LY-570310, MP-424,VX-950 ()
VX 950 ()
MP 424 ()
VRT 111950 ()
Incivo ()
LY 570310 ()
VRT-111950 ()
Telaprevir-d4 ()
P&D ID
PD009331
CAS
402957-28-2
Tags
available
covalent binder
drug
Approved by
FDA
EMA
First approval
2011
Drug indication
Liver disease
Hepatitis C virus infection
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Inhibits the hepatitis C viral enzyme NS3.4A serine protease but also has a recent repurposing claim for cathepsin A inhibition . (GtoPdb)
DESCRIPTION Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].
PRICE 230
DESCRIPTION Telaprevir (Incivek) (VX-950) is an effective inhibitor of HCV NS3-4A serine protease (IC50: 0.35 ??M).
DESCRIPTION Kinesin-1 modulator; cell permeable (Tocris Bioactive Compound Library)
DESCRIPTION Telaprevir is an NS3/4A viral protease inhibitor used in combination with other antivirals for the curative treatment of chronic Hepatitis C Virus infections. (Enamine Bioactive Compounds)
DESCRIPTION Telaprevir (Incivek) (VX-950) is an effective inhibitor of HCV NS3-4A serine protease (IC50: 0.35 μM). (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
3
Compound Sets
25
AdooQ Bioactive Compound Library
A10902
Cayman Chemical Bioactives
31317
ChEMBL Approved Drugs
CHEMBL231813
ChEMBL Drugs
CHEMBL231813
CovalentInDB
CI006861
CovBinderInPDB
CBR000002
CBR000003
CBR001103
CBR001104
CBR001105
CBR002272
CBR003676
CBR007181
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB05521
DrugBank Approved Drugs
DB05521
DrugCentral
4173
DrugCentral Approved Drugs
4173
DrugMAP
DMMRV29
DrugMAP Approved Drugs
DMMRV29
Enamine Bioactive Compounds
EBC-27428
EU-OPENSCREEN Bioactive Compound Library
EOS101607
Guide to Pharmacology
7871
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL231813
MedChem Express Bioactive Compound Library
HY-10235
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
Telaprevir(VX-950)
TargetMol Bioactive Compound Library
T6190
Tocris Bioactive Compound Library
6658
Withdrawn 2.0
w204
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
679.41
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
4
Rotatable Bonds
13
Ring Count
5
Aromatic Ring Count
1
cLogP
2.45
TPSA
179.56
Fraction CSP3
0.72
Chiral centers
6.0
Largest ring
6.0
QED
0.23
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HCV
HCV NS3-4A serine protease
SARS-CoV
CTSA, PGR
COVID-19,HCV Protease
HCV Protease
Primary Target
Other Proteases
MOA
Inhibitor
HCV inhibitor
Indication
hepatitis C
ATC
J05AE11
Pathway
Anti-infection
Metabolic Enzyme/Protease
Microbiology/virology
Proteases/Proteasome
Source data